Track market-moving stories before they get noisy

24.06K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

ATLANTA--(BUSINESS WIRE)---- $QMLS #NASDAQ--QumulusAI (Nasdaq: QMLS), a neocloud infrastructure provider purpose-built for the AI computing era, today announced it has expanded its equipment lease financing with Tech Finance Co., LLC (“TFC”) to approximately $123.6 million, up from the $26.0 million announced May 7, 2026. The three-year leases fund NVIDIA Blackwell GPUs the company announced purchasing in May and July 2026. TFC financed 85% to 90% of equipment cost on each lease schedule, and customer deposits f.

CHARLOTTE, N.C., Oct. 20, 2026 /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced that Chief Financial Officer Mike Maguire and Chief Wholesale Banking Officer Kristin Lesher will speak at the BancAnalysts Association of Boston (BAAB) Conference on Thursday, Nov. 5, 2026, at 10:25 a.m.

On its third-quarter 2026 earnings call, held on Oct. 16, 2026, Truist (TFC -0.58%) announced a strategic plan to exit non-core lending businesses and reallocate capital toward relationship banking. For long-term investors, the shift aims to improve return on capital, lower credit risk, and boost earnings quality across its Sun Belt branch network.

Three takeaways from management explain how the strategy unfolds.

1. Exiting Non-Core Consumer Lending Frees Up CapitalTruist agreed to sell $7.7 billion in LightStream unsecured loans after closing its Regional Acceptance Corp. subprime auto loan portfolio sale. Exiting stand-alone lending units will lower credit risk and free up capital for higher-return relationship banking.

Similar to our decision to sell RAC, the sale of LightStream represents an exit from a non-core loan-only business that is generating returns well below our targets. Exiting LightStream will also improve our credit risk, liquidity, and funding profiles.
-- Mike Maguire, Chief Financial Officer2. Balance Sheet Repositioning Reduces Risk and Supports ReturnsManagement is reinvesting proceeds from portfolio sales to shift securities out of low-yielding mortgage-backed securities, which are pools of residential mortgages, into potentially shorter-duration U.S. Treasuries. The bank is also paying down high-cost wholesale borrowings, which are short-term corporate funding obligations.

With respect to the balance sheet, we plan to remix our securities away from long-dated MBS into a greater mix of U.S. Treasuries, limit the use of our deposits to core strategic lending areas where we can build deep, long-standing relationships...
-- Mike Lyons, Chief Executive Officer3. Spending Discipline Creates Capacity for Growth InvestmentsManagement is reviewing every business and process to cut low-priority overhead expenses. The savings will fund branch renovations, technology upgrades, and commercial banker hires to win daily demand deposit accounts, which are low-cost checking accounts.

The goals are really twofold: to enhance the balance sheet, which Mike talked about a lot, and we're happy with the progress we made this quarter. Then really take our current expense base and create incremental capacity within it...
-- Mike Lyons, Chief Executive OfficerLooking AheadA dense branch network across Southeastern markets and full-service commercial banking provide a strong operational foundation. Long-term strategy focuses on deposit growth, expense discipline, and capital efficiency.

We have all the raw materials to become one of the country's top-performing banks, and this is our overwhelming No. 1 objective.
-- Mike Lyons, Chief Executive OfficerFuture value hinges on disciplined resource allocation to boost profitability without expanding risk. Management remains focused on meeting return on tangible common equity, a key bank profitability metric.

We remain committed to delivering on our ROTCE targets, which includes 15% in 2027 and 16%-18% over the long term.
-- Mike Lyons, Chief Executive OfficerThe Motley Fool has positions in and recommends Truist Financial. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, recently announced the expansion of its collaboration with Truist, one of the largest US-based financial services companies, to support the bank's continued build-out of its AI-first Global Capability Center in Hyderabad. Together with Infosys, Truist is strengthening India's role as a key global hub for innovation, talent, and digital capability.

Through this expanded collaboration, Infosys will utilize its deep financial services expertise and AI-first capabilities, to help accelerate scalable transformation and drive enterprise-wide value creation. As part of this effort, Truist is consolidating capabilities currently delivered through multiple supplier relationships in India into a more unified, integrated operating model. Infosys and Truist will celebrate the successful onboarding of more than 1,000 colleagues later this month, marking a significant milestone in the continued growth and expansion of the GCC.

The GCC represents Truist's continued investment in building a scaled, future-ready innovation and operations hub designed to enhance client experiences, empower teammates, and help deliver a more digitally enabled and relationship-driven banking experience. Infosys will enable Truist to build, scale, and transition a self-sustaining center of excellence, integrating AI, technology, data, and operations into a single cohesive delivery framework. This model is designed to reduce third-party dependency, manage global delivery complexity, and cultivate deep, future-ready technology talent.

India represents a critical part of Truist's evolving operating model, with a strong base of Truist contract professionals already contributing across engineering, data, and operations. Building on its long-standing relationship with Truist, Infosys will support the continued scaling of Truist's GCC, helping to enable seamless cross-geography collaboration and faster delivery in an increasingly digital and AI-driven industry.

Steve Hagerman, Chief Information Officer, Truist, said, "Our Global Capability Center in India is a strategic investment in Truist's future. As we accelerate our transformation into a more agile, AI-enabled enterprise, we are intentionally building global capabilities that allow us to move faster, innovate at scale, and better serve our clients. This center will play a critical role in helping Truist build and scale strategic capabilities through a more integrated operating model improving client experience and empowering teammates. Through this collaboration with Infosys, we are building not just capacity, but enduring expertise that strengthens how we operate as a global organization."

Dennis Gada, EVP and Global Head of Banking and Financial Services, Infosys, said, "We are proud to deepen our long-standing relationship with Truist as they evolve their presence in India into a strategic engine for AI-led transformation and reimagination. Financial institutions today must move decisively from modernizing legacy infrastructure to deploying AI at scale across every function. By leveraging Infosys Topaz, our proven Build, Operate and Transfer enablement model and deep financial services expertise, we are committed to helping Truist build a resilient, scalable digital core - and unlock AI value at scale - with trust and governance-built in."

About Truist

https://www.truist.com/ Truist Financial Corporation (NYSE: TFC) is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $556 billion as of June 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

About Infosys

Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY) is a global leader in AI first business consulting and technology services. Over 325,000 of our people work to amplify human potential and create the next opportunity for people, businesses, and communities. As navigators of enterprise transformation, we enable businesses in 59 countries to unlock AI value at scale. With over four decades of experience in managing the systems and workings of global enterprises, we accelerate business transformation through our AI-first value framework, deep domain expertise, and our unique ability to orchestrate innovations from our AI-native partner ecosystem. Infosys is recognised as the fastest growing IT services brand globally, committed to being a well-governed, environmentally sustainable partner for our clients where deep talent expertise, in an inclusive workplace, help them navigate their next.

Safe Harbor

Certain statements in this release, including those concerning our future events, future growth prospects, our future financial or operating performance and our offerings and collaborations are "forward looking statements" intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current expectations, assumptions, estimates and projections about the Company, our industry, economic conditions in the markets in which we operate, and certain other matters. These forward-looking statements are subject to substantial known and unknown risks, uncertainties and other factors, that could cause actual results or outcomes to differ materially from those implied by such forward-looking statements. Important factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements include, but are not limited to, risks and uncertainties regarding the execution of our business strategy, increased competition for talent, our ability to attract and retain personnel, increase in wages, investments to reskill our employees, our ability to effectively implement a hybrid work model, economic uncertainties and geo-political situations, technological disruptions and innovations such as artificial intelligence, the complex and evolving regulatory landscape including immigration regulation changes, particularly in the United States, our Environmental, Social, Governance ("ESG") vision, our capital allocation policy and expectations concerning our market position, future operations, margins, profitability, liquidity and capital resources, our corporate actions including acquisitions, cybersecurity matters, the outcome of pending litigation and the US government investigation, and the effect of current and future tariffs. These and additional factors that may cause actual results or outcomes to differ from those implied by the forward-looking statements are discussed in more detail in our US Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2026. These filings are available at www.sec.gov. In light of these and other uncertainties, you should not conclude that the results or outcomes referred to in any of the forward-looking statements will be achieved. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.

SOURCE Infosys

Truist Financial Corporation (TFC) Q3 2026 Earnings Call October 16, 2026 8:00 AM EDT

Company Participants

Bradley Milsaps - Executive VP & Head of Investor Relations
Michael Lyons - President, CEO & Director
Michael Maguire - Senior EVP & CFO

Conference Call Participants

Ryan Nash - Goldman Sachs Group, Inc., Research Division
Robert Scott Siefers - TD Cowen, Research Division
Manan Gosalia - Morgan Stanley, Research Division
L. Erika Penala - UBS Investment Bank, Research Division
Kenneth Usdin - Bernstein Autonomous LLP
Michael Mayo - Wells Fargo Securities, LLC, Research Division
John Pancari - Evercore ISI Institutional Equities, Research Division
Ebrahim Poonawala - BofA Securities, Research Division

Presentation

Operator

Greetings, ladies and gentlemen, and welcome to the Truist Financial Corporation Third Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this event is being recorded. It is now my pleasure to introduce your host, Mr. Brad Milsaps.

Bradley Milsaps
Executive VP & Head of Investor Relations

Thank you, Betsy, and good morning, everyone. Welcome to Truist's Third Quarter 2026 Earnings Call. With us today are our CEO, Mike Lyons; and our CFO, Mike Maguire. During this morning's call, they will discuss Truist's third quarter 2026 results, share their perspectives on current business conditions and provide an updated outlook for 2026. The accompanying presentation as well as our earnings release and supplemental financial information are available on the Truist Investor Relations website, ir.truist.com.

Our presentation today will include forward-looking statements and certain non-GAAP financial measures. Please review the disclosures on Slides 2 and 3 of the presentation regarding these statements and measures as well as the appendix for required reconciliations to GAAP.

With that, I'll turn it over to Mike Lyons.

Michael Lyons
President, CEO & Director

Thanks, Brad, and good morning, everyone. It's good to be with you on my first earnings call. I've long admired Truist and its predecessor companies, and

, /PRNewswire/ -- Stock Preachers News Commentary - Wall Street closed a volatile week split sharply down the middle. The Dow finished Friday at 52,134.63, down 0.08% on the day but still up 0.93% for the week, while the Nasdaq Composite tumbled 1.28% Friday and 3.64% for the week, its worst stretch in months. The S&P 500 fell 1.43% weekly and the Russell 2000 dropped 2.43%. The VIX climbed to 17.02 and the VXN jumped to 22.89, underscoring the growing divide between mega-cap tech weakness and broader market resilience. Active Companies from around the markets with current developments this week include: Lockheed Martin (NYSE: LMT), Beretta Holding S.A. (NYSE: RGR), Truist Financial Corporation (NYSE: TFC), CLPS Incorporation (Nasdaq: CLPS), and Orvana Minerals Corp. (TSX: ORV).

Friday's session showed the market's split personality in real time. The S&P 500 slid 0.58% to 7,699.50, pulling back from its week high of 7,821.67 and testing its 50-day EMA support near 7,681.97. The Nasdaq's 1.28% Friday drop capped a week that erased nearly 1,000 points, closing at 26,370.53 against a week high of 27,376.66, with RSI14 down to 40.4, signaling fading momentum.

Small caps lagged further, with the Russell 2000 down 1.03% Friday and 2.43% on the week, closing at 2,738.83 with an RSI14 of just 33.5, deep in weaker territory. The Dow bucked the trend, holding a 0.93% weekly gain and an 8.47% year-to-date advance, closing just under resistance at 52,281.19 and above its 50-day EMA support at 52,017.10.

Commodities sent mixed signals too. Gold slipped 0.10% for the week to $4,186.50 an ounce while silver fell 4.38% to $57.51. WTI crude jumped 4.17% weekly to $97.65 a barrel, up 70.06% year-to-date, while the 10-year Treasury yield eased 13 basis points to 5.11%, even as it ticked up 2 basis points on the day.

The full report breaks down the key support and resistance levels traders are watching next week along with sector-by-sector sentiment across the divided market.

CONTINUED... Read this and more news at: https://stockpreachers.com/articles/a-week-that-split-the-market-right-down-the-middle/

In other industry developments and happenings in the market this week include:

Lockheed Martin (NYSE: LMT) Lockheed Martin delivered a C-130J-30 Super Hercules aircraft to the U.S. Navy at its Marietta, Georgia facility on Oct. 15, marking the start of its transformation into the E-130J Phoenix II, the Navy's next-generation TACAMO mission platform for airborne nuclear command and control.

The aircraft will next be transferred to Northrop Grumman, the mission systems integrator, to complete the conversion. "This delivery marks a historic milestone for the U.S. Navy, Lockheed Martin, and the nation's strategic communications network," said Trish Pagan, vice president of Lockheed Martin's Air Mobility & Maritime Missions.

The delivery revives the link between the TACAMO mission and the Hercules family, which previously flew the mission via the EC-130Q variant from 1963 until 1993.

Beretta Holding S.A. (NYSE: RGR) Beretta Holding announced preliminary results of its cash tender offer for shares of Sturm, Ruger & Company at $44.80 per share. The offer, which expired Oct. 15, sought up to 2,400,184 shares but drew 3,589,647 shares validly tendered, excluding 2,652,256 shares tendered by notice of guaranteed delivery.

Because the offer was oversubscribed, Beretta Holding estimates a preliminary proration factor of approximately 38.45%, subject to confirmation by the depositary following the guaranteed delivery period.

"This investment represents a significant milestone for Beretta Holding. It marks our first participation in a publicly listed company and opens a new chapter in our development as a long-term investor in the U.S. capital markets," said Pietro Gussalli Beretta, Chairman and CEO of Beretta Holding.

Truist Financial Corporation (NYSE: TFC) Truist Financial Corporation reported its third quarter 2026 results, with details available through its earnings release, investor presentation and Quarterly Performance Summary posted to the company's investor relations website.

The company hosted a live earnings call at 8 a.m. ET the same day, with a replay made available on its website for 30 days.

Truist describes itself as a top-10 commercial bank with total assets of $554 billion as of Sept. 30, 2026, offering consumer and small business banking, commercial and corporate banking, investment banking, wealth management, payments and specialized lending.

CLPS Incorporation (Nasdaq: CLPS) CLPS Incorporation reported full fiscal year 2026 revenue growth of 4.7% year-over-year to $172.2 million, and second-half revenue growth of 6.6% to $87.1 million, despite revenue pressure from the downsizing of a key client's China Solution Centers.

Revenue from customized IT solution services surged 113.9% year-over-year to $5.9 million for the full year, while revenue generated outside mainland China rose 47.5% to $62.7 million, with Hong Kong SAR up 61.0% to $23.2 million and Japan up 122.7% to $4.5 million.

"Fiscal 2026 was a pivotal year of structural transition and resilience for CLPS," said Raymond Lin, Chief Executive Officer of CLPS. "Since becoming a publicly traded company in 2018, we have expanded our topline from $48.9 million to $172.2 million, delivering a robust 17.0% compound annual growth rate over the past eight years."

Orvana Minerals Corp. (TSX: ORV) Orvana Minerals Corp. reported fourth quarter and fiscal 2026 production results, with consolidated FY2026 production of 45,160 gold equivalent ounces, comprised of 39,282 gold ounces, 3.1 million pounds of copper and 112,499 silver ounces.

Orovalle produced 37,775 ounces of gold and 2.9 million pounds of copper in FY2026, exceeding gold production guidance of 34,000 to 37,000 ounces and landing within copper guidance of 2,700 to 3,000 thousand pounds. EMIPA produced its first dore and copper cathodes from the expanded Don Mario Plant during the quarter but came in below the company's FY2026 guidance, which was withdrawn on September 17, 2026.

"Looking ahead to FY2027, our focus remains on sustaining disciplined production performance and operational efficiency while managing inflationary cost pressures arising from broader global conditions and continued workforce challenges."

Sign-up up free for timely articles like this delivered directly to your inbox at: https://StockPreachers.com

Contact Information:

https://stockpreachers.com

Media Contact: [email protected]

DISCLAIMER: Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. This article is being distributed by Stock Preachers, which is wholly owned and operated by Market Equities Limited ("MEL"), a company incorporated under the laws of Ireland. Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice. Information in this article was obtained from sources believed to be reliable, including company news releases and public market data, but its accuracy cannot be guaranteed. Market data is as of the time stated and may be delayed. Investing in securities involves risk, including the possible loss of some or all of your investment. Technical analysis describes past price and volume behaviour and does not predict future results; support and resistance levels can fail at any time. Nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to company executives are reproduced from those companies' own news releases. Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company's filings with the SEC and applicable Canadian securities regulators.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nasdaq-posts-worst-weekly-drop-in-months-as-dow-edges-to-a-narrow-gain-302911550.html

SOURCE Stock Preachers

Key Takeaways TFC's Q3 adjusted EPS rises 11.5% y/y but misses estimates amid securities losses and costs.Truist's NII rises to $3.66B, while record wealth income and 3.6% deposit growth support results.TFC returns $1.8B to shareholders and projects Q4 revenues of $5.35B, with NII of $3.65B-$3.70B.
Truist Financial’s (TFC - Free Report)  third-quarter 2026 adjusted earnings of $1.16 per share rose 11.5% from the prior-year quarter. However, the bottom line missed the Zacks Consensus Estimate by a penny.

The reported quarter’s results excluded a pre-tax loss of $1.4 billion or 90 cents per share on the sale of available-for-sale securities, along with a pre-tax loan loss reserve recapture of $581 million or 36 cents per share and a pre-tax impact of $106 million or 6 cents per share from the Regional Acceptance Corporation (RAC) loan sale.

Third-quarter 2026 results benefited from higher net interest income (NII), record quarterly wealth management income and higher average deposits. Securities losses and higher non-interest expenses were the undermining factors.

After considering the non-recurring items, net income available to common shareholders was $684 million, or 56 cents per share, compared with $1.35 billion, or $1.04 per share, in the prior-year quarter.

TFC’s Revenue Mix Reflects Securities LossesTotal adjusted taxable-equivalent revenues were $5.30 billion, rising 1.3% from the prior-year quarter. GAAP revenues of $3.75 billion declined from $5.19 billion a year ago.

NII was $3.66 billion compared with $3.63 billion in the third quarter of 2025. Taxable-equivalent NII rose 0.7% year over year to $3.71 billion, driven by fixed asset and liability repricing, higher client deposit balances and higher loan balances, partly offset by lower loan spreads and unfavorable deposit mix.

The net interest margin (NIM) contracted 1 basis point year over year to 3.00%.

Non-interest income was $84 million, down substantially from $1.56 billion a year ago, primarily reflecting the securities losses and the RAC loan sale losses. Adjusted non-interest income increased 2.5% to $1.60 billion.

Wealth management income rose 8.8% year over year to $407 million, card and treasury management fees increased 2.1% to $347 million, and lending-related fees grew 16.5% to $120 million. Investment banking (IB) and trading income was $324 million, up 0.3%.

Truist Financial’s Cost Trends Show Higher ExpensesNon-interest expenses totaled $3.11 billion, up 3% from $3.01 billion a year ago. This was primarily due to higher personnel expenses, professional fees and outside processing costs. Adjusted non-interest expenses, excluding $40 million of RAC loan sale costs, were $3.07 billion, up 1.7%.

Profitability metrics weakened alongside reported earnings. Return on average common equity was 4.7% and return on average tangible common equity was 7.2% in the quarter compared with 9% and 13.6%, respectively, in the prior-year period.

The efficiency ratio deteriorated to 82.9% from 58.1% in the prior-year quarter.

TFC’s Credit Quality: A Mixed BagThe company recorded a benefit for credit losses of $253 million against a provision of $436 million a year ago, reflecting a $581-million allowance release related to the RAC loan sale. The allowance for loan and lease losses was 1.25% of loans and leases held for investment, down from 1.54% a year ago.

Net charge-offs (NCOs) were $629 million, up from $385 million in the year-ago quarter. The NCO ratio of 0.77% of average loans and leases increased 29 basis points year over year. Excluding RAC, the NCO ratio was 0.38%.

Total non-performing assets were $1.34 billion as of Sept. 30, 2026, down from $1.63 billion a year earlier. Non-performing loans and leases were 0.40% of loans and leases held for investment, down 8 basis points year over year.

TFC’s Balance Sheet & Capital Returns Remain in FocusAverage loans and leases were $329.46 billion, up from $322.07 billion in the year-ago quarter. Average loans and leases held for investment were $325.52 billion, up 1.6% year over year. Period-end loans and leases held for investment were $323.93 billion.

Average deposits were $410.70 billion, increasing 3.6% from $396.60 billion a year earlier. End-of-period deposits were $413.23 billion, up from $394.91 billion a year ago.

The common equity Tier 1 ratio was 10.7% at the quarter-end, down 20 basis points sequentially and 30 basis points year over year.

Truist Financial returned $1.8 billion to shareholders during the quarter through $0.6 billion of common dividends and $1.2 billion of share repurchases.

TFC Provides Q4 ProjectionsFor the fourth quarter of 2026, management expects taxable-equivalent revenues of $5.35 billion and NII of $3.65-$3.70 billion. The NII outlook reflects a $125-million reduction from the RAC loan sale and a $40-million increase from the securities repositioning.

Non-interest expenses are projected to rise 2.5% sequentially. The company estimates an NCO ratio of 0.45% and an effective tax rate of 13.5%.

Management expects $1 billion in share repurchases in the fourth quarter. The outlook excludes the impacts of potential strategic actions.

Our Take on Truist FinancialHigher NII, growth in average deposits and record wealth management income supported Truist Financial’s adjusted quarterly results. However, securities losses and increased non-interest expenses weighed on reported performance. The completed RAC loan sale improved asset quality metrics, while the planned LightStream loan sale represents a further portfolio action.

Truist Financial currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance of Major BanksBank of America’s (BAC - Free Report) third-quarter 2026 adjusted earnings of $1.08 per share missed the Zacks Consensus Estimate of $1.11. In the prior-year quarter, the company reported earnings of $1.04.

Bank of America witnessed dismal trading performance this time around due to weaker fixed-income trading. Similarly, amid weakness in advisory and debt underwriting activities, BAC’s IB business performance was not good.

While BAC’s capital markets business performance was not impressive this time, year-over-year growth in NII drove total revenues. Provisions declined in the quarter on a year-over-year basis, which was a positive, but non-interest expenses increased, creating another major headwind.

JPMorgan’s (JPM - Free Report) third-quarter 2026 adjusted earnings of $5.75 per share missed the Zacks Consensus Estimate of $5.94. After considering the net investment securities losses of 18 cents, earnings were $5.57 per share, up 9.9% from a year ago.

JPM’s reported net revenues of $50.17 billion rose 8% year over year. Strong equity trading performance, IB activity and loan growth supported revenues, while the fixed income trading business was subdued. While JPMorgan recorded a year-over-year rise in expenses in the quarter, it witnessed a decline in provisions, which aided the results to some extent.

Truist Financial Corporation (TFC - Free Report) came out with quarterly earnings of $1.16 per share, missing the Zacks Consensus Estimate of $1.17 per share. This compares to earnings of $1.04 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -0.86%. A quarter ago, it was expected that this company would post earnings of $1.08 per share when it actually produced earnings of $1.23, delivering a surprise of +13.89%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Truist Financial, which belongs to the Zacks Banks - Major Regional industry, posted revenues of $5.19 billion for the quarter ended September 2026, missing the Zacks Consensus Estimate by 2.19%. This compares to year-ago revenues of $5.19 billion. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Truist Financial shares have lost about 5.4% since the beginning of the year versus the S&P 500's gain of 13.1%.

What's Next for Truist Financial?While Truist Financial has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Truist Financial was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.21 on $5.29 billion in revenues for the coming quarter and $4.67 on $21.03 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Banks - Major Regional is currently in the bottom 33% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Northern Trust Corporation (NTRS - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2026. The results are expected to be released on October 21.

This company is expected to post quarterly earnings of $2.86 per share in its upcoming report, which represents a year-over-year change of +24.9%. The consensus EPS estimate for the quarter has been revised 0.8% higher over the last 30 days to the current level.

Northern Trust Corporation's revenues are expected to be $2.26 billion, up 11.8% from the year-ago quarter.

For the quarter ended September 2026, Truist Financial Corporation (TFC - Free Report) reported revenue of $5.19 billion, up 0.1% over the same period last year. EPS came in at $1.16, compared to $1.04 in the year-ago quarter.

The reported revenue represents a surprise of -2.19% over the Zacks Consensus Estimate of $5.31 billion. With the consensus EPS estimate being $1.17, the EPS surprise was -0.86%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Truist Financial performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Efficiency ratio: 82.9% versus 58.2% estimated by five analysts on average.Book Value Per Share (BVPS): $46.78 versus $48.35 estimated by four analysts on average.Net charge-offs as a percentage of average loans and leases: 0.8% compared to the 0.7% average estimate based on four analysts.Tier 1 Capital Ratio: 12% versus the three-analyst average estimate of 12%.Total nonperforming assets: $1.34 billion versus $1.89 billion estimated by three analysts on average.Total nonaccrual loans and leases: $1.31 billion compared to the $1.83 billion average estimate based on three analysts.Average balance - Total earning assets: $491.43 billion compared to the $495.09 billion average estimate based on three analysts.Tier 1 Leverage Ratio: 9.6% compared to the 9.6% average estimate based on three analysts.Total Capital Ratio: 13.6% compared to the 13.8% average estimate based on two analysts.Total Noninterest Income: $1.53 billion compared to the $1.65 billion average estimate based on five analysts.Net interest income: $3.66 billion versus $3.67 billion estimated by five analysts on average.Net interest income (FTE): $3.71 billion compared to the $3.71 billion average estimate based on four analysts.View all Key Company Metrics for Truist Financial here>>>

Shares of Truist Financial have returned -3.9% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Executive appointments enhance Truist's leadership as the company sharpens its strategic priorities and invests for its next phase of growth

, /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced executive leadership appointments to complement the bank's existing team as it focuses on its next phase of growth.

The appointments build on Truist's strengths in consumer and small business banking and support the company's continued focus on growing core deposits, deepening primary banking relationships and investing in the capabilities that serve clients.

"Truist has all the ingredients to become one of the top-performing banks in the country, and these executive appointments will help ensure we have the leadership depth, organization structure and accountability to execute with discipline," said Mike Lyons, president and chief executive officer.

Leadership Appointments
D. Steve Boland will join Truist as vice chair, working across the company to help advance the bank's strategic agenda and support execution of the highest-priority initiatives. Boland brings more than three decades of financial services experience to Truist. Prior to retiring from Bank of America in 2025, Boland was chief administrative officer of the company and was previously president of Retail Banking.

Shimna Sameer, who Truist previously announced would join to lead Truist Wealth, will become chief consumer banking officer. Prior to joining Truist, Sameer spent more than 20 years in key consumer banking, wealth management and private banking roles at Bank of America. She will lead Truist's efforts to grow core deposits, deepen primary banking relationships and strengthen the client experience and capabilities that support them. Jeff Dunn, head of Truist Private Banking, Specialty Wealth & Institutional, and Bryan Cram, head of Truist Wealth Brokerage, will act as co-heads of Truist Wealth on an interim basis, reporting to Chief Wholesale Banking Officer Kristin Lesher.

Jeff Warner will join Truist as chief small business banking officer. Warner joins from PNC Financial Services Group, where he spent more than 25 years serving small business, corporate and public finance clients and leading large-scale operations teams. Most recently, Warner served as head of small business for PNC.

"We have tremendous strengths, including deep client relationships, an attractive branch footprint, talented teammates and businesses with significant potential. These leaders have demonstrated track records driving growth and operational excellence," said Lyons.

Boland, Sameer and Warner will each report to Lyons.

Dontá Wilson, Truist's chief consumer and small business banking officer, will be leaving the bank. Truist is grateful for Dontá's leadership, how he has positioned the business and the many contributions he has made to the company and its communities.

About Truist
Truist Financial Corporation (NYSE: TFC) is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $554 billion as of Sept. 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

Funds will help provide immediate relief and support longer-term recovery across Gulf Coast communities

, /PRNewswire/ -- In response to approaching Hurricane Isaias and the threat it poses to communities along the Gulf Coast, Truist Foundation today announced a $250,000 donation for immediate relief and longer-term recovery efforts. The funding will be distributed among the American Red Cross, Center for Disaster Philanthropy and United Way Worldwide to help impacted communities respond to and recover from the storm.

Current forecasts show Hurricane Isaias approaching the northern Gulf Coast, with impacts potentially including damaging winds, storm surge and heavy rainfall.

"When disaster strikes, communities need support in the immediate aftermath, but they also need partners committed to the recovery that follows," said Namrata Yadav, chief culture and philanthropy officer at Truist. "By working alongside organizations with deep expertise and strong community connections, we can help meet critical needs now while supporting the longer-term work of rebuilding and strengthening communities."

Truist Foundation takes a comprehensive approach to disaster response that spans community preparation, immediate relief and long-term recovery. Working with nonprofit partners, the Foundation helps address needs such as food, shelter, health care and emergency financial assistance, as well as longer-term needs including home repairs and rebuilding.

Truist teammates are also encouraged to volunteer in communities impacted by disasters. For teammates directly affected, the Truist One Team Fund provides short-term financial assistance for significant financial hardship resulting from eligible events, including natural disasters. In 2025, 275 teammate grant requests were fulfilled, totaling $797,000. Funding is provided through a combination of Truist Foundation support and individual teammate contributions.

To learn more about how Truist Foundation responds to disasters with urgency, purpose and a long-term commitment to recovery, visit TruistFoundation.org.

About Truist Foundation

Truist Foundation is committed to Truist Financial Corporation's (NYSE: TFC) purpose to inspire and build better lives and communities. The Foundation makes strategic philanthropic investments in a wide variety of nonprofit organizations centered around two focus areas: building career pathways to economic mobility and strengthening small businesses to ensure all communities have an opportunity to thrive. Learn more at TruistFoundation.org.

SOURCE Truist Foundation

Truist Financial Corporation (NYSE:TFC) will release earnings for its third quarter before the opening bell on Friday, Oct. 16.

Analysts expect the Charlotte, North Carolina-based company to report quarterly earnings of $1.07 per share, up from $1.04 per share in the year-ago period. The consensus estimate for TFC’s quarterly revenue is $5.36 billion. It reported $5.24 billion last year, according to Benzinga Pro.

On Sept. 17, Truist announced redemption of subordinated notes due Oct. 2026.

Truist Financial shares fell 1.5% to close at $45.58 on Wednesday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

UBS analyst Erika Najarian maintained a Neutral rating and cut the price target from $55 to $50 on Oct. 5, 2026. This analyst has an accuracy rate of 63%. JP Morgan analyst Vivek Juneja maintained an Underweight rating and cut the price target from $54 to $50.5 on Oct. 2, 2026. This analyst has an accuracy rate of 57%. Evercore ISI Group analyst John Pancari maintained the stock with an Outperform rating and slashed the price target from $56 to $54 on Oct. 1, 2026. This analyst has an accuracy rate of 61%. Stephens & Co. analyst Andrew Terrell maintained an Overweight rating and raised the price target from $54 to $54 on July 29, 2026. This analyst has an accuracy rate of 66%. Baird analyst David George maintained the stock with a Neutral rating and increased the price target from $55 to $56 on July 20, 2026. This analyst has an accuracy rate of 72%. Considering buying TFC stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Truist Financial has held its dividend frozen since 2022 while rivals PNC and U.S. Bancorp hand shareholders raises, and the reason why reveals a capital strategy that splits income investors right down the middle.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Truist Financial (NYSE:TFC | TFC Price Prediction) has paid $0.52 per quarter on every ex-dividend date since August 11, 2022. Over the same stretch, management has kept raising its buyback target, which now stands at $5 billion for 2026, up from $4 billion. For income investors, the open question is whether any of that excess capital ever reaches the dividend.

A 4.5% Yield That Has Been Frozen Since 2022 At $46.33, the $2.08 annualized payout yields about 4.5%. PNC Financial Services (NYSE:PNC) yields roughly 3.6% at its new $2.00 quarterly rate. U.S. Bancorp (NYSE:USB) yields about 3.6% at $0.52 a quarter. Truist’s coverage is solid. Second-quarter diluted EPS came in at $1.23, up 37% year over year, so the dividend took up only about 42% of quarterly earnings.

Buybacks Are Getting Every Spare Dollar Truist bought back $1.1 billion of stock in Q1 and $1.2 billion in Q2. On the July call, CFO Mike Maguire defended the pace:

“If you look at our buyback at $5 billion, we’re pretty elevated, right? We’ve got a total net payout ratio above 100%. By the way, we think that’s appropriate, given our capital position.”

CET1 capital rose to 10.9%. Truist wants that ratio at 10% by the end of 2027, which Maguire said “implies that we’re going to continue to return a significant amount of capital to shareholders throughout the rest of this year and next year.” The call included no announcement of a dividend change.

Its peers are taking a different route. PNC raised its dividend 18% in July, and CEO William S. Demchak called the increase “further evidence of the strength and resilience of our franchise.” U.S. Bancorp planned a ~4% increase for Q3 2026, subject to board approval, while repurchasing only $200 million in Q2.

What the Share Price Is Pricing In Truist trades at about 12x 2025 EPS of $3.82, while PNC and U.S. Bancorp trade near 13x. That small discount helps explain the buyback push. The shares are down 2.96% year to date, while PNC is up 8.02% and U.S. Bancorp is up 11.53%. Over five years, Truist is down 1.94%. Investors are paying for a yield and remain doubtful about growth.

Credit Trends and a New CEO Could Change the Math Nonperforming loans rose to 0.50% in Q1, and net charge-offs climbed to 0.61%, driven by commercial construction. U.S. Bancorp’s ratio was 0.53% and PNC’s was 0.25%. Truist also cut its outlook for net interest income growth to 1% to 1.5%, citing an unfavorable deposit mix.

Mike Lyons was slated to become CEO on September 1, 2026. Bill Rogers, CEO at the time of the call, said: “Let’s let Mike come in and talk about what he wants to do.”

Three developments would undermine the case: charge-offs running well above the 55 bps guidance, CET1 falling to 10% ahead of schedule, or ROTCE missing the greater than 14% 2026 target.

What Income Investors Can Expect From the Dividend The dividend looks safe, and it is likely to stay at $0.52. Earnings cover it more than twice, and management has made clear that buybacks come first until CET1 reaches its target. Retirees get the highest yield of the three banks but no raises. The first real signal on growth will come from the new CEO’s capital plan, most likely alongside third-quarter results.

Contact [email protected] for any questions or corrections.

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Truist Financial Corporation (TFC - Free Report) , which belongs to the Zacks Banks - Major Regional industry.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 11.99%.

For the most recent quarter, Truist Financial was expected to post earnings of $1.08 per share, but it reported $1.23 per share instead, representing a surprise of 13.89%. For the previous quarter, the consensus estimate was $0.99 per share, while it actually produced $1.09 per share, a surprise of 10.10%.

Price and EPS Surprise

For Truist Financial, estimates have been trending higher, thanks in part to this earnings surprise history. And when you look at the stock's positive Zacks Earnings ESP (Expected Surprise Prediction), it's a great indicator of a future earnings beat, especially when combined with its solid Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Truist Financial has an Earnings ESP of +0.01% at the moment, suggesting that analysts have grown bullish on its near-term earnings potential. When you combine this positive Earnings ESP with the stock's Zacks Rank #3 (Hold), it shows that another beat is possibly around the corner. The company's next earnings report is expected to be released on October 16, 2026.

With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores, developed alongside the Zacks Rank, are complementary indicators that rate stocks based on three widely-followed investing methodologies; they also help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.8% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Truist Financial Corporation (TFC - Free Report) Truist Financial, formed after the “merger of equals” deal between BB&T Corp and SunTrust Banks in December 2019, is one of the largest commercial banks in the United States. The company, headquartered in Charlotte, NC, conducts business operations primarily through its bank subsidiary, Truist Bank, and a few other non-bank subsidiaries.

TFC is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 10.19; value investors should take notice.

For fiscal 2026, three analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.03 to $4.62 per share. TFC boasts an average earnings surprise of +8%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, TFC should be on investors' short list.

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of disease progression (non-significant p=0.144) and TFC showed a 61% slowing of disease progression (nominal p=0.008) ~ 

~ Updated data reflecting all 15 high-dose patients showed substantial treatment effect on both cUHDRS and TFC at 36 months, the timepoint that is the regulatory anchor for the submitted BLA and the confirmatory study; the new analysis demonstrated 80% slowing of disease progression based on cUHDRS (nominal p=0.005) and 67% based on TFC (nominal p=0.011) ~ 

 ~ Treatment effect at 48 months likely understated by substantial missing data and survivor bias in updated external control; post hoc analysis using prior external control showed slowing of disease of 54% on cUHDRS (nominal p=0.041) and 68% on TFC (nominal p=0.001) at 48 months ~

~ These positive data are meaningful for Huntington's disease patients who currently have no approved disease-modifying treatment options ~

~ Investor conference call and webcast today at 8:30 a.m. ET ~

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced additional data from the ongoing Phase I/II studies of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

"Four years after a single administration, ifezuntirgene inilparvovec continues to show meaningful slowing of disease progression, further strengthening our conviction in its benefit for people living with Huntington’s disease," stated Walid Abi-Saab, M.D., chief medical officer of uniQure. "At 48 months, Total Functional Capacity (TFC), the primary measure of our confirmatory study, demonstrated consistent slowing of functional decline, with the absolute treatment benefit maintained in Month 48. Furthermore, the observed differences between the high and low doses on both composite Unified Huntington’s Disease Rating Scale (cUHDRS) and TFC are consistent with a dose-dependent treatment effect. The updated 36-month analysis, which now includes three additional high-dose patients, showed a substantial effect on cUHDRS and TFC, further reinforcing the data included in our license applications. We believe these data are clinically meaningful for Huntington’s disease patients, and we look forward to presenting them at a future scientific meeting."

Topline Clinical Data at 36 months and 48 months1

Today's announcement comprises results from the ongoing Phase I/II studies at two timepoints, with a data cutoff of June 30, 2026. Twenty-nine patients have been treated with ifezuntirgene inilparvovec (n=17 high dose; n=12 low dose) across the studies’ first two cohorts. The new 36-month analysis now includes 15 high-dose and 12 low-dose patients, with three additional high-dose patients having reached that timepoint since the September 2025 analysis. The 48-month analysis includes 12 patients at each dose.

Outcomes for the 36-month and 48-month analyses were compared to propensity score-matched external controls (n=1,337 for high dose) from an updated ENROLL-HD natural history dataset with a September 2025 cutoff. As is common with longitudinal natural history studies, missingness of data increased with duration of follow-up, reaching 53% in the updated ENROLL-HD matched controls at 48 months. The Company’s analysis of the updated control showed that patients discontinuing follow-up were progressing materially faster than those remaining in the control group. The Company believes these factors likely understated disease progression in the control and the resulting treatment effect of ifezuntirgene inilparvovec at 48 months.

At the June 2026 Type B meeting, the FDA communicated that the 36-month data from 12 high-dose patients would be acceptable as the primary basis for the BLA submission under the accelerated approval pathway, and the submission was made accordingly. The BLA submission of ifezuntirgene inilparvovec predated the topline results announced today and these results were not part of the submission.

High-Dose Results at 36 Months (n=15)

cUHDRS showed 80% slowing of disease progression compared to the updated external control (nominal p=0.005). Treated patients had a mean change in cUHDRS from baseline of -0.28 compared to a change of -1.39 for the external control, a favorable treatment difference of 1.12 compared to baseline. TFC showed 67% slowing of disease progression compared to the updated external control (nominal p=0.011). Treated patients had a mean change in TFC from baseline of -0.27 compared to a change of -0.82 for patients in the propensity score-matched external control, a favorable treatment difference of 0.55 compared to baseline.Mean cerebrospinal neurofilament light protein (CSF NfL) was 6% below baseline (n=14). High-Dose Results at 48 Months (n=12)

cUHDRS showed a 44% slowing of disease progression compared to the updated external control and did not reach statistical significance (p=0.144). Treated patients had a mean change in cUHDRS from baseline of -0.90 compared to a change of -1.61 for the external control, a favorable treatment difference of 0.71 compared to baseline.TFC showed 61% slowing of disease progression compared to the updated external control (nominal p=0.008). Treated patients had a mean change in TFC from baseline of -0.37 compared to a change of -0.94 for the external control, a favorable treatment difference of 0.57 compared to baseline.In a post-hoc sensitivity analysis using the prior ENROLL-HD external control, the 48-month analysis showed 53.5% slowing based on cUHDRS (nominal p=0.041) and 68.3% based on TFC (nominal p=0.001).Mean cerebrospinal neurofilament light protein (CSF NfL) was 4% above baseline (n=11). Dose Comparison at 48 Months (high dose n=12, low dose n=12)

The observed differences between the high and low doses are consistent with a dose-dependent treatment effect. At 48 months, mean change from baseline in cUHDRS was –0.91 in high-dose patients compared with −1.94 in low-dose patients, a difference of 1.03 in favor of the high dose. Mean change from baseline in TFC was −0.30 in high-dose patients compared with −0.70 in low-dose patients, a difference of 0.40 in favor of the high dose. "Huntington’s disease does not slow on its own; the biology is one of inevitable progressive decline," stated Victor Sung, M.D., professor of neurology at the University of Alabama at Birmingham (UAB), director of the UAB Huntington’s Disease Clinic. "What I find particularly notable in the expanded data is the consistently meaningful treatment effect at 36 months, and the apparent stability of the functional capacity benefit through Month 48. We see this even as the rate of decline in the updated comparator dataset slowed, an anticipated shift which appears to reflect some attrition in the longitudinal external control data, and which does not reflect the typical clinical presentation of accelerating decline over time. Total Functional Capacity tracks things that matter the most to patients and families – ability to work, perform household chores and handle daily self-care activities. Seeing that treatment difference maintained at four years is meaningful for people living with this relentlessly progressive degenerative disease."

Ifezuntirgene inilparvovec continues to be generally well-tolerated, with a manageable safety profile at both doses. The most common adverse events in the treatment groups were related to the administration procedure, and all have resolved. As previously disclosed, five high dose participants (17%) experienced a treatment-related serious adverse event (SAE) related to central nervous system inflammation, all of which fully resolved.

Since the September 2025 data readout, one suicide in a low-dose patient occurred, approximately five years after receiving treatment. This was assessed as unrelated to treatment by the study investigator. Suicidal ideation and completed suicide occur at substantially elevated rates in Huntington’s disease relative to the general population, and suicide is among the leading causes of death in those with the disease.

Investor Conference Call and Webcast Information 

uniQure management will host an investor conference call and webcast today, Tuesday, September 29 at 8:30 a.m. ET. The event will be webcast under the Events & Presentations section of uniQure’s website at https://www.uniqure.com/investors-media/events-presentations, and following the event a replay will be archived for 90 days. Analysts wishing to participate in the question and answer session should access the live call by dialing (646) 307-1963 or toll-free (800) 715-9871 and entering conference ID 5075555. If you are joining the conference call, please join 15 minutes before the start time.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen). Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.2, EU3, and the UK4, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "establish," "estimate," "expect," "goal," "intend," "look forward to," "may," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and similar expressions and the negatives of those terms. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the factors that likely understate disease progression in the updated ENROLL-HD controls and the Company’s belief that ifezuntirgene inilparvovec meaningfully reduces disease progression based on its evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: risks related to the Company’s Phase I/II clinical trials of ifezuntirgene inilparvovec, including the risk that such trials will be unable to continue to demonstrate data sufficient to support further clinical development or regulatory approval; the risk that the FDA ultimately concludes that the Phase I/II trial data are not sufficient to support a BLA or accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the initiation, timing and progress of clinical trials and pathways to regulatory approval; whether the measurements that the Company is evaluating are viewed as robust and sensitive measurements of disease progression; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved; the Company’s effectiveness in managing current and future clinical trials and regulatory processes; the Company’s ability to demonstrate the therapeutic benefits of its gene therapy candidates in clinical trials; the continued development and acceptance of gene therapies; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s ability to fund its operations and to raise additional capital as needed and on acceptable terms. These risks and uncertainties are more fully described under the heading "Risk Factors" in the Company’s periodic filings with the U.S. Securities & Exchange Commission ("SEC"), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:   FOR INVESTORS:FOR MEDIA:  Chiara Russo
Direct: 781-491-4371
Mobile: 617-306-9137
[email protected]
Tom Malone
Direct: 339-970-7558
Mobile:339-223-8541
[email protected]
   1 cUHDRS is the pre-specified primary endpoint for the 48 months analysis; all other p-values are nominal. The 36-month data included 15 high-dose patients; the 48-month analysis included 12 high-dose patients. Percentage slowing was sensitive to the magnitude of decline in the external control.
2 Yohrling G, et al. Neurology 2020;94(15 Suppl):954.
3 Medina A, et al. Mov Disord 2022;37(12):2327–2335
4 Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.

Michael P. Lyons, President & CEO of Truist Financial Corporation (TFC +0.93%), executed a direct purchase of 21,000 shares of common stock on Sept. 17, 2026, according to an SEC Form 4 filing.

Transaction summaryMetricValueShares purchased21,000Transaction value$1.0 millionPost-transaction shares (directly held)21,000Post-transaction value$1.02 millionTransaction value based on SEC Form 4 weighted average purchase price ($48.36); post-transaction value based on Sept. 17, 2026 market close ($48.45).

Key questionsHow does this purchase align with the executive's total equity exposure?
While the direct common stock holding stands at 21,000 shares, Lyons holds a larger position in derivative securities, specifically 266,990 restricted stock units that vest in installments through 2030.What was the execution price relative to the market close?
The 21,000 shares were acquired at a weighted-average price of $48.36, slightly below the market close price of $48.45 on the day of the transaction.Does this transaction represent a change in the insider's direct ownership?
Because no prior direct holdings were reported in this filing, the transaction effectively establishes a new direct common stock position of 21,000 shares for the President & CEO.What does the transaction size indicate about management's capital allocation?
The ~$1.0 million investment in personal capital signals a discretionary increase in direct exposure to the regional bank, which currently has an insider ownership percentage of 0.0017%.Company OverviewMetricValueShare Price (as of market close 2026-09-17)$48.45Market Capitalization$60.4 billionRevenue (TTM)$30.5 billionNet Income (TTM)$5.8 billionCompany SnapshotTruist Financial Corporation provides a comprehensive suite of banking and trust services, including deposit products, lending solutions, wealth management, and insurance offerings, with revenue primarily derived from net interest income, non-interest income from fees and commissions, and insurance operations.The company operates a diversified financial services business model structured across three primary segments--Consumer Banking and Wealth, Corporate and Commercial Banking, and Insurance Holdings--generating earnings through traditional banking spreads, advisory fees, and insurance underwriting activities.Truist serves a broad customer base, including individual consumers, small- and mid-market businesses, large corporations, and institutional clients throughout the Southeastern and Mid-Atlantic regions of the United States.Truist Financial Corporation is a major regional financial institution with $60.4 billion in market capitalization and $30.5 billion in TTM revenue, operating as a diversified banking and financial services holding company. The organization maintains a strategic presence across high-growth markets in the Southeast and Mid-Atlantic, leveraging its integrated business model to deliver comprehensive financial solutions across consumer, commercial, and wealth management segments. With approximately 37,849 employees and a demonstrated net income of $5.8 billion TTM, Truist maintains a competitive position through its regional market expertise and diversified revenue streams spanning traditional banking, wealth management, and insurance operations.

What this transaction means for investorsThere is one class of insider transactions that catches my attention more than others. That's insider buys. It's because insider sales are often quite complex, involving tax implications and estate planning. However, insider purchases are fairly straightforward. If an insider is buying, they are backing their conviction in a company's stock with their own money. Nonetheless, retail investors shouldn't blindly follow suit. Instead, they should review a company's fundamentals. With that in mind, let's have a closer look at Truist Financial (TFC).

First, let's review how TFC stock has performed in recent years. Since 2021, TFC stock has generated a total return of 15%, equating to a compound annual growth rate (CAGR) of 2.9%. The S&P 500, meanwhile, has delivered an 88% total return, with a 13.4% CAGR.

Premium Feature

Moneyball Superscore

68/100

Today's Change

(

0.93

%) $

0.45

Current Price

$

49.01

Turning to its key metrics, TFC's core fundamentals paint a mixed picture. As for the positives, the company has aggressively bought back shares. Its current $5 billion share repurchase program has enabled the company to reduce its overall share count by 8.5% over the last five years. Second, TFC has a current dividend yield of 4.3%, which will appeal to income-oriented investors. Last, insider purchases, including CEO Michael Lyon's $1.0 million purchase, demonstrate management's confidence.

On the flip side, there are some concerns. For one, TFC's net interest margin (NIM) is at 2.98%. That's below average and falling. In addition, credit quality could be weakening as borrowers continue to face macroeconomic challenges from rising prices.

In summary, investors must weigh this mixed picture. Income-oriented investors may be tempted by the company's stout dividend yield and encouraged by insider buying, while skeptical investors may view the stock as underperforming and facing macroeconomic headwinds.

, /PRNewswire/ -- Truist Bank (NYSE: TFC) today announced it will redeem all $850,000,000 principal amount outstanding of its fixed rate subordinated notes due Oct. 30, 2026, (CUSIP 07330MAA5) on the redemption date of Sept. 30, 2026.

The redemption price for the subordinated notes will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date. Interest on the subordinated notes will cease to accrue on and after the redemption date.

Payment of the redemption price for the subordinated notes will be made through the facilities of The Depository Trust Company.

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $556 billion as of June 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

On September 16, 2026, Truist Financial Corp TFC shares fell 4.0% today, closing at $48.44. The stock has traded within a 52-week range of $40.79 to $56.20, highlighting its volatility over the past year. This recent decline comes against a backdrop of a 1.5% year-to-date increase and a 13.4% increase over the past year.

GF Value™ verdict: Current price is $48.44, with GF Value™ at $51.77, indicating a 6.4% undervaluation.GF Score™ of 60/100 signifies an above-average rating, suggesting potential for improvement.Insider activity shows that insiders sold $2.7M worth of shares over the past 12 months, with no purchases, indicating potential caution among insiders.Is TFC Overvalued or Undervalued?Truist Financial Corp's current price of $48.44 is assessed against a GF Value™ estimate of $51.77, suggesting that the stock is currently undervalued by 6.4%. This margin of safety provides an opportunity for investors who believe in the long-term fundamentals of the company. GF Value™ is GuruFocus' proprietary intrinsic-value estimate, which takes into account historical trading multiples, the company's past growth, and projections for future performance. The GF Valuation label indicates that TFC is fairly valued, which adds a layer of complexity; while the stock is undervalued based on GF Value™, the overall fair valuation implies caution regarding future growth prospects.

However, investors should note that the company's Financial Strength is rated at 2/10, which may raise concerns about its stability and ability to sustain dividends in the long run. Thus, while the current price relative to GF Value™ presents a buying opportunity, caution is warranted given the low financial strength rating.

How Does TFC's Valuation Compare to Its History?MetricCurrentHistoricalP/E (TTM)11.1x11.7xForward P/E9.7xN/ATruist's current P/E ratio of 11.1x is slightly below its 5-year median of 11.7x, indicating that the stock is trading at a lower valuation compared to its historical standards. The forward P/E of 9.7x further reinforces this perspective of relative undervaluation. This analysis aligns with the GF Value™ verdict, suggesting that TFC is undervalued based on its historical valuation metrics.

What Does TFC's GF Score™ Tell Us?The GF Score™ measures a company's overall financial health and growth potential, incorporating multiple factors to provide a comprehensive view of its performance. Truist's GF Score™ of 60/100 reflects an above-average positioning, though it also highlights significant areas for improvement, especially in financial strength and growth.

MetricRatingGF Score™60Financial Strength2/10Profitability4/10Growth2/10Valuation9/10Momentum10/10The strongest aspect of TFC's score is its Valuation rank at 9/10, indicating that the stock is relatively cheap compared to its intrinsic value. Conversely, the Financial Strength and Growth ranks of 2/10 raise concerns about the company's stability and growth trajectory. This dichotomy between a strong valuation and weak financial health suggests that while the stock may be attractive from a price perspective, underlying risks could impact long-term performance.

What Are Gurus and Insiders Doing with TFC?Currently, 11 gurus hold positions in Truist Financial Corp, with 5 adding to their stakes and 5 trimming their positions in recent quarters. This mixed activity indicates a cautious sentiment among professional investors. Guru 13F activity, a unique feature of GuruFocus, provides insight into how experienced investors are positioning themselves with TFC.

In contrast, insider activity shows that insiders sold $2.7M worth of shares over the past year, with no insider buying reported during this time. This selling trend could suggest a lack of confidence from management in the company's near-term prospects or a desire to realize gains, which may be a red flag for potential investors. Overall, the combination of guru activity and insider selling presents a mixed signal regarding the company's future.

What This Means for InvestorsBased on the GF Value™ analysis, Truist Financial Corp TFC is currently undervalued with a fair value estimate of $51.77 compared to its current price of $48.44, signaling a potential opportunity for investors. However, the low financial strength rating and negative insider activity warrant careful consideration of the risks involved in maintaining a position in this stock. For those interested in a potential dividend stock, the sustainability of the dividend amidst these factors should be a key consideration.

For a more comprehensive analysis of Truist Financial Corp TFC, visit the stock page for detailed insights, including the GF Value™ page and the GuruFocus Stock Screener.

Frequently Asked QuestionsWhat is TFC's GF Score™?

TFC's GF Score™ is 60/100, indicating an above-average rating and suggesting that the company has potential for improvement in various aspects of its business.

Is TFC overvalued or undervalued?

TFC is currently undervalued, with a GF Value™ of $51.77 compared to its current price of $48.44, offering a 6.4% margin of safety.

What is TFC's P/E ratio?

The P/E ratio for TFC is 11.1x, which is below its 5-year median P/E of 11.7x, indicating that the stock is trading at a lower valuation compared to its historical metrics.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

On CNBC’s “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Target Corporation (NYSE:TGT).

According to recent news, Target on Monday reported that Mark Weinstein has joined the company as chief marketing and guest experience officer.

On the earnings front, Target reported quarterly earnings of $2.46 per share on Aug. 19, beating the analyst consensus estimate of $2.33 per share. The company reported quarterly sales of $26.539 billion, which beat the analyst consensus estimate of $26.141 billion.

Don’t forget to check out our premarket coverage here

Stephanie Link, chief investment strategist, head of investment solutions and equity portfolio manager at Hightower Advisors, named Truist Financial Corporation (NYSE:TFC) as her final trade.

Lending support to her choice, Truist Financial posted better-than-expected second-quarter earnings on July 17. The bank earned $1.23 per diluted share in the second quarter, clearing the analyst consensus of $1.08 per share. Revenue of $5.27 billion edged past the $5.24 billion consensus estimate and came in 4.67% above the year-ago figure.

Trending

Shannon Saccocia, Neuberger, recommended iShares U.S. Healthcare ETF (NYSE:IYH).

Price Action:

Target shares fell 2.7% to close at $154.40 on Tuesday. Truist Financial shares gained 0.7% to close at $50.46 during the session. iShares U.S. Healthcare ETF slipped 0.1% on Tuesday. Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Truist Financial Corporation (TFC) Barclays 24th Annual Global Financial Services Conference September 15, 2026 10:30 AM EDT

Company Participants

Michael Maguire - Senior EVP & CFO

Conference Call Participants

Jason Goldberg - Barclays Bank PLC, Research Division

Presentation

Jason Goldberg
Barclays Bank PLC, Research Division

If everyone could take their seats, we'll continue with this morning's strong run of large-cap bank speakers. Next up, very pleased to have Truist Financial. From the company, the Chief Financial Officer, Mike Maguire. Mike, welcome.

Michael Maguire
Senior EVP & CFO

Yes. Thank you, Jason, for having me.

Question-and-Answer Session

Jason Goldberg
Barclays Bank PLC, Research Division

For those that may not have seen this morning, Truist posted a slide. And I guess to me, the 2 biggest takeaways were, one, they announced the sale of $5.5 billion of auto loans, representing substantially all the assets of the Regional Acceptance Corp., basically a subprime auto unit. They also mentioned the quarter is tracking as expected. So Mike, is that correct? And maybe just maybe fill us in on some details of the kind of strategic rationale, financial considerations of the transaction and maybe any updates on the quarter?

Michael Maguire
Senior EVP & CFO

Yes, great. So absolutely right. We did affirm this morning with our slide that we are affirming the quarter and the year, so no outlook changed. Now that obviously doesn't take into consideration the transaction impacts related to Regional Acceptance. But just to talk maybe a little bit about RAC. We are under contract to sell the $5.5 billion in near-prime auto loans and essentially exit that business entirely. As we thought about this business and you think about the year so far and some of the decisions that we've made around stopping originations in marine and rec vehicle lending, deemphasizing some of our national prime auto lending businesses. This was, in

Truist Financial, a top 10 commercial bank in the United States in terms of assets, disclosed Tuesday (Sept. 15) that it is selling $5.5 billion worth of auto loans and exiting the near-prime auto lending business.

Key Takeaways Truist Financial shares rose 15% in six months, but underperformed its broader industry and close peers.TFC expects 10% fee-income growth in 2026, helped by IB, trading and wealth management.TFC faces rising expenses and weaker credit quality, making an attractive entry point preferable.
Truist Financial Corporation (TFC - Free Report) shares have gained 15% over the past six months, in line with the S&P 500 Index’s rally. The industry to which the stock belongs has gained 27.8%.

If we compare TFC’s price performance with two of its close peers, Bank of America Corporation (BAC - Free Report) and The Bank of New York Mellon Corporation (BNY - Free Report) , it appears that the stock has underperformed both. Over the past six months, BAC and BNY shares have rallied 34.2% and 40%, respectively.

6-Month Price Performance

Image Source: Zacks Investment Research

Despite underperforming the broader industry, TFC’s performance has been decent over the past six months. Now, let us find out if the stock has upside potential left. In order to understand this, let us dig deep into its fundamentals and growth prospects.

Key Positives of TFCNet Interest Income (NII) Growth: Supported by growth in loans and higher rates, Truist Financial’s NII has demonstrated a relatively stable growth trajectory, witnessing a 0.9% compound annual growth rate (CAGR) over the five years ended 2025, with momentum continuing into the first half of 2026.

Management has moderated its 2026 NII growth outlook, primarily reflecting the continued optimization of less strategic lending portfolios, lower loan spreads, a less favorable deposit mix and changes in the forward rate curve. However, these headwinds appear manageable and hence solid loan demand and the ongoing repricing of deposits are likely to continue to provide support to funding costs and spread income as the rate cycle evolves.

This is reflected in management’s expectation for 1.5% sequential NII growth in the third quarter of this year.

Improving Fee Income: Following the 2024 divestiture of its insurance business, Truist Financial has been placing greater emphasis on recurring, client-driven fee income to diversify its revenue mix and reduce reliance on spread income. Excluding securities losses, its non-interest income saw a 1.9% CAGR from 2019 to 2025, supported by the Truist merger, and continued strength in wealth management and other fee-based businesses.

Momentum has continued into the first half of this year, with management expecting non-interest income to rise 10% in 2026, an upgrade from its previous high-single-digit growth outlook.

The improved view reflects stronger performance across investment banking (IB), trading and wealth management, while greater connectivity across commercial, corporate and IB should create additional opportunities for cross-selling and recurring client fees.

Strategic Investments & Digital Transformation: Truist Financial continues to reposition its franchise toward higher-growth, higher-return opportunities, supported by its multi-year investment program launched in 2025 to expand talent, build commercial pipelines and strengthen digital capabilities in attractive markets.

The strategy has already gained traction, as middle-market deposits rose 12% year over year in second-quarter 2026, including 27% growth in expansion markets such as Texas, Pennsylvania and Ohio.

At the same time, the company is using digitalization and AI as operating levers rather than simply technology initiatives. Truist Assist usage increased 60% year over year to nearly 2 million interactions in the second quarter. AI-enabled tools, including Truist Insights, Truist Assist and call summarization, are helping reduce routine service workloads and improve employee productivity, creating capacity to reinvest in higher-value client activities.

Together, targeted market expansion, stronger digital engagement and AI-driven productivity should support higher-quality revenue growth and operating leverage, providing a potential catalyst for improved profitability over the longer term.

Strong Balance Sheet: Truist Financial entered 2026 with a large, diversified balance sheet and a solid liquidity position. As of June 30, 2026, the company held $39.3 billion in cash and due from banks and interest-bearing deposits against $69.9 billion of total debt, with only 38.5% classified as short-term.

Supported by its robust liquidity position, the company continues to prioritize capital returns while maintaining adequate regulatory buffers. Following the successful completion of the 2026 Federal Reserve stress test, TFC maintained its quarterly dividend at 52 cents per share, underscoring confidence in the strength and resilience of its capital position.

It also has significant capacity for share repurchases, with $7.7 billion remaining under its $10-billion authorization as of June 30, 2026, and management targeting $5 billion in buybacks in 2026.

What’s Hurting TFC’s Growth?Rising Expenses: Truist Financial’s cost base has stabilized from the elevated post-merger levels, supported by roughly $750 million of gross savings from its 2023 strategic cost-saving program. However, non-interest expenses rose in 2025 and the first half of 2026, driven by higher personnel costs, and continued investments in technology and digital capabilities, including AI-enabled tools.

Expense Trend

Image Source: Zacks Investment Research

While these investments could support productivity over the longer term, continued reinvestment may limit operating leverage and constrain bottom-line growth. With management expecting non-interest expenses to increase 1.75% in 2026, persistent cost pressures remain a headwind to earnings expansion.

Deteriorating Credit Quality: Truist Financial’s credit quality has been weakening, as reflected in sharply higher loss provisioning and charge-offs. Over the three years ended 2025, provision for credit losses and net charge-offs (NCOs) saw a CAGR of 34.6% and 27.5%, respectively, driven by an increasingly unfavorable macro backdrop.

While provisions declined in the first six months of 2026, NCOs increased. Given the still-challenging operating environment, provisions and NCOs will likely remain elevated and trend higher in the near term.

Analyzing Analyst Sentiments for TFCAnalysts do not seem optimistic regarding the company’s earnings growth potential. Over the past 30 days, the Zacks Consensus Estimate for TFC’s 2026 earnings has been unchanged at $4.58, while the 2027 estimate has been revised lower to $4.93.

Earnings Estimate Revision

Image Source: Zacks Investment Research

Here’s How to Approach TFC Stock NowBacked by lower funding costs, steady loan demand and growth in fee-based businesses, Truist Financial remains well-positioned to deliver top-line growth. Its decent liquidity supports sustainable capital distributions. Strategic restructuring initiatives, investments in digital capabilities and expansion in high-growth markets will further support revenue prospects.

However, elevated expenses due to higher personnel costs and continuous investment in technology will likely keep hurting Truist Financial's bottom line in the near term. A challenging macroeconomic environment could strain its financial performance and lead to weakening credit quality, posing another concern.

Thus, investors should not rush to buy the TFC stock now. Instead, they should keep it on their radar and wait for an attractive entry point. Those who already own the TFC stock can hold on to it because it is less likely to disappoint over the long term, given its strong fundamentals.

At present, Truist Financial carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

AI Call Summaries handle the note-taking so care center teammates can focus on clients, resolving needs faster and delivering more personalized service.

, /PRNewswire/ -- Truist Financial Corp. (NYSE: TFC) today announced the full deployment of AI Call Summaries across its care centers, using generative AI to automatically convert client conversations into concise, structured summaries within seconds. By handling the note-taking and post-call documentation automatically, the technology frees care center teammates to stay fully present with clients, resolve needs faster and deliver more personalized, informed service on every call.

Truist has fully deployed AI Call Summaries across its care centers. Since its implementation in the third quarter of 2025, the capability has scaled rapidly, generating more than 4.5 million summaries, in the second quarter of 2026 alone, and supporting more than 70% of care center inbound client interactions. The average Truist care center phone call lasts more than eight minutes, making the ability to quickly capture key themes, client needs and resolution outcomes particularly valuable. Based on average time savings of approximately 30 seconds per call, AI Call Summaries saved teammates more than 36,000 hours in the second quarter of 2026.

"At Truist, listening to clients is central to how we improve the experience across the client journey," said Truist Head of Digital, Client Experience, and Marketing Sherry Graziano. "By using AI-powered capabilities, we can consolidate feedback, organize insights and get answers to clients more efficiently. This is a great example of being digitally empowered yet deeply relational, equipping teammates with the tools they need to serve our clients with greater care."

Across Truist Care Centers, AI Call Summaries help teammates access key information from prior interactions and prepare for follow-up conversations. "Deploying generative AI-powered call summaries across our care centers is a meaningful step forward in how we support our teammates and serve our clients," said Truist Head of Truist Care Centers Kimberly Dorsett. "Instead of manually capturing conversation details, teammates can use AI-generated summaries to quickly understand and respond to clients with greater confidence."

AI Call Summaries represent a foundational step in Truist's broader strategy to embed AI into everyday workflows, improve the client experience and reimagine how work gets done across the organization. As one of Truist's earliest enterprise-scale generative AI applications approved for broad use, the capability reflects the bank's commitment to scaling AI responsibly. Truist plans to extend the capability to additional areas of the bank, demonstrating how targeted AI use cases can deliver immediate value while creating a foundation for greater operational consistency, institutional knowledge capture and better decision-making across the organization."

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top 10 commercial bank with $549 billion as of March 31, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation